To reflect the molecular details and clinical differences of each subtype and to include all three subtypes into the best applicable taxonomy, we propose to rename the previous CNS embryonal tumor with PLAGL amplification (ET, PLAGL) to CNS embryonal tumor with PLAG family gene alteration (ET, PLAG)—along with the specification of the respective subtype—PLAG1-fused, PLAGL1-amplified, or PLAGL2-amplified. Here, PLAGL2 is linked to neoplasm.